UroGen Announces Subgroup Analysis Results For ENVISION Study Of UGN-102 In LG-IR-NMIBC; Comparable CR Rates And DOR Observed Across Tumor Burden And Focality Levels

BenzingaFeb 14 14:34 ET

UroGen Announces Results From Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

BusinesswireFeb 14 14:30 ET

Express News | D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target

BenzingaFeb 12 10:16 ET

Insider Sale: Chief Medical Officer of $URGN Sells 1,896 Shares

Quiver QuantitativeFeb 4 12:01 ET

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen PharmaJan 30 00:00 ET

Express News | UroGen Highlights Results From Study On Durability Of Response From Post-Commercialization Of JELMYTO Titled 'Durability of Response of UGN-101: Longitudinal Follow-Up of Multicenter Study'

BenzingaJan 22 08:08 ET